Improved glycaemic control of thrice‐daily biphasic insulin aspart compared with twice‐daily biphasic human insulin; a randomized, open‐label trial in patients with type 1 or type 2 diabetes

Abstract

This trial confirmed that a thrice-daily BIAsp regimen can safely be used to intensify treatment for patients inadequately controlled on twice-daily BHI. A treat-to-target trial is required to explore the full potential of the BIAsp regimens and evaluate their use as a viable alternative to intensification with a basal-bolus regimen.

The Pharmacokinetic and Pharmacodynamic Properties of Different Formulations of Biphasic Insulin Aspart: A Randomized, Glucose Clamp, Crossover Study

“…30 Furthermore, BIAsp therapy has even been shown to achieve glycemic control equivalent to that of basal-bolus therapy using insulin aspart and NPH insulin. 31 In this study, the BIAsp group administered BIAsp 50 or 70 (depending on body mass index) at breakfast and lunch, plus BIAsp 30 at dinner, which resulted in a mean HbA 1c reduction of 1.3% in 16 weeks-the same as that for the basal-bolus group, indicating that different mixture ratios help to achieve major reductions in HbA 1c .…”

Switching to biphasic insulin aspart 30/50/70 from biphasic human insulin 30/50 in patients with type 2 diabetes in normal clinical practice: observational study results

“…One advantage of using mid-/high-mix formulations is that they offer a greater insulin load around mealtimes and, therefore, better postprandial glucose control 2 . The use of BIAsp 30/50/70 has been investigated in several RCTs, which have shown that glycemic control can be improved by switching to BIAsp (three-times daily) from BHI therapy (twice daily), although there may be a higher risk of minor hypoglycemia [31][32][33][34] . The results of these studies also indicate that it may be better to use BIAsp 30 for the evening dose to decrease the risk of nocturnal hypoglycemia 20 .…”

6thAnnual Symposium on Self-Monitoring of Blood Glucose (SMBG) Applications and Beyond, April 25–27, 2013, Riga, Latvia

“…Chadha showed data from two recent studies demonstrating clear benefits of high ratio premixed insulins on postprandial glucose profile and overall metabolic control in people with type 2 diabetes. 51,52 Keynote Lecture: The Selfish Brain-Conflicting Interests Between Brain and Body Can Help to Explain Why Diets Often Fail Achim Peters, Luebeck, Germany…”